Latest Safety News

ABx Group’s mixed rare earth carbonate from Tasmania’s Deep Leads project has earned strong validation from US-based Rare Earth Technologies Inc, confirming its high purity and compatibility with cutting-edge separation technology.

Finder Energy has confirmed the technical feasibility of repurposing the Petrojarl I FPSO vessel for its Kuda Tasi and Jahal oil fields, setting the stage for a final investment decision by mid-2026.

Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Immutep Limited has successfully completed the single ascending dose phase of its IMP761 trial, showing promising safety and immunosuppressive effects in healthy volunteers. The biotech’s novel LAG-3 agonist could reshape autoimmune disease treatment.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Western Gold Resources has formalised critical road access agreements enabling ore haulage from its Gold Duke Project to nearby processing facilities, marking a significant step forward in project development.

Critical Resources Limited has validated its amorphous solid-state electrolyte, demonstrating stable lithium-metal interface performance over 1,200 hours and efficient ionic conductivity at room temperature, marking a significant step in solid-state battery development.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

West African Resources has reported a robust A$567 million net profit after tax for 2025, driven by strong gold production and operational cash flow. The successful ramp-up of the Kiaka gold production centre and sustained output from Sanbrado underpin the company’s positive outlook for 2026.

WA Kaolin Limited reported a $5.06 million half-year loss despite a 257% revenue surge, grappling with operational setbacks and regulatory challenges. The company’s recent debt restructuring and trading suspension signal a critical juncture as it seeks to stabilise and recapitalise.